BY
POSTED ON
March 19, 2021
Here is a look at how the Biden administration’s agriculture policy agenda will impact the biotechnology sector and members of BIO.
BY
POSTED ON
February 25, 2021
Mapillar Dahn has three daughters—and they all have sickle cell disease.
But she gained hope thanks to Global Blood Therapeutics (GBT) drug Oxbryta, the first FDA-approved drug targeting the underlying cause of sickle cell disease rather than just its symptoms.
Dahn’s oldest daughter, Tully, was…
Latest From Industry Experts
BY
POSTED ON
March 31, 2021
BY
POSTED ON
March 26, 2021
BY
POSTED ON
March 19, 2021
Latest From Our Events
